Phase 3 Study Shows Burosumab is Superior than Traditional Therapies for X-Linked Hypophosphatemia (XLH)

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email